GlassScriptPhysician profile
Frank Jongsu Won
NPI 1285751420
$3,158.44
in general payments reported to CMS, 2019-2025
14 companies · $818 in 2025
The $818 reported for 2025 was more than what 88% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2020: $174 · 2021: $165 · 2022: $458 · 2023: $491 · 2024: $792 · 2025: $818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,100.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,243.15 | 2019-2025 | Total30, Dailies Total1, Precision 1 |
| Bausch & Lomb Americas INC. | $421.49 | 2022-2025 | Miebo, Xiidra, Infuse |
| Visioneering Technologies, INC. | $328.78 | 2019-2020 | |
| Coopervision INC. | $326.77 | 2022-2025 | Myday Contact Lens, Clariti Contact Lens |
| Sun Pharmaceutical Industries INC. | $234.70 | 2022-2025 | |
| Sight Sciences, INC. | $163.38 | 2022 | |
| Aerie Pharmaceuticals, INC. | $122.47 | 2021 | |
| Harrow Eye, LLC | $104.56 | 2024-2025 | Vevye |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $93.47 | 2019-2021 | |
| Oyster Point Pharma, INC. | $37.47 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $33.16 | 2024 | Xdemvy |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Novartis Pharmaceuticals Corporation | $16.99 | 2022 | |
| Abbvie INC. | $12.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Won listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.